Last reviewed · How we verify
Akkermansia muciniphila
At a glance
| Generic name | Akkermansia muciniphila |
|---|---|
| Sponsor | Yu Chen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation (PHASE1)
- Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers (NA)
- Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease (PHASE4)
- Evaluation of HB05P for Muscle Strength Improvement in Older Adults (NA)
- Research on Probiotics in Improving Obesity (NA)
- Probiotics in Obesity Management (NA)
- Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity (NA)
- An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Akkermansia muciniphila CI brief — competitive landscape report
- Akkermansia muciniphila updates RSS · CI watch RSS
- Yu Chen portfolio CI